Condition: Chronic Pain · Opioid Use Disorder · Sponsor: Yale University
The primary objective of this phase 2 study is to investigate the therapeutic potential of orally administered combined delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in relieving both pain and cue-induced opioid craving in people with co-occurring opioid use disorder (OUD) and chronic pain who are undergoing methadone therapy.
This description comes directly from the study's public registry record.
Julia V. Meyerovich, M.S. · 203-932-5711 · julia.meyerovich@yale.edu
Joao P. De Aquino, M.D. · 203-623-7493 · joao.deaquinolima@yale.edu
Always discuss trial participation with your own doctor first.
| Connecticut Mental Health Center | New Haven, Connecticut, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06544291